Recombinant SARS-Cov-2 Variant Bank
Several new variants of SARS-CoV-2 virus have emerged in recent months. The alpha variant B.1.1.7, the beta variant B.1.351, the gamma variant P.1, and the most recent delta variant B.1.617 are of particular concern because of their high prevalence. A subset of the mutations identified in the RBD domain of the spike protein occurs in more than one strain. These convergent mutations are of high interest because they may be the cause of the increased transmissibility. Sino Biological has launched RBD and spike proteins of these variants, along with a new panel of corresponding neutralizing antibodies for variant neutralization and characterization.
The mutations in these strains also occur in the nucleocapsid protein, which is commonly used as the biomarker in rapid antigen tests. It’s critical to assess whether the current commercial antigen tests can detect the mutated N proteins with the same sensitivity and specificity as their WT counterpart.
Sino Biological has developed a panel of recombinant RBD/Spike and nucleocapsid protein variants which can be used to evaluate the efficacy of the antibodies and vaccination.
This content was supplied by Sino Biological.
Submit Your Research to the F1000Research Disease Outbreaks Gateway
Contribute to the global understanding of disease outbreaks with the F1000Research Disease Outbreaks Gateway. With trusted publishing, open access, and transparent peer review, your research will uphold the highest standards of integrity while advancing knowledge in areas like COVID-19 and other public health challenges.
Join a platform that values rigor, transparency, and author control. Submit your research today at F1000Research Disease Outbreaks Gateway.